New Brunswick Scientific Co., Inc. (NBSC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	7/29/2000 5:55:29 PM
From: scaram(o)uche	Read Replies (1) of 724

from a GENZ 424B5 (whatever that is), filed 3/23/00...... In January 1998, we non-exclusively licensed an assay to Merck & Co. relating to methods for identifying small molecules that interfere with the binding of the MDM2 protein with the p53 protein. We received an up-front fee for this license and could receive approximately $8 million in milestone payments if the defined development milestones are achieved by Merck for a product developed by a method licensed from us or covered by our patent rights. In addition, we would receive royalties on worldwide sales of any developed products. Relating to this from the DGI site...... DGI has successfully identified peptide and scFv agonists and antagonists for a number of biologically important molecules including Growth Hormone Receptor (human and "animal"), Insulin Receptor (IR), IgA receptor, TNF receptors RI and RII and the IL-6 receptor. The Diogenesis® process has also been used to isolate peptides that inhibited the interaction of the important cell cycle protein p53 with MDM2. DGI has also successfully screened approximately 100,000 small molecules using SDAs for growth hormone.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next